Experts are calling for further investigation into glucagon-like peptide-1 receptor agonist (GLP-1) medications as potential cancer prevention agents after a study found a 41% reduction in obesity-related cancer risk among users. The research, published in the *Annals of Oncology*, analyzed data from over 161,000 obese patients who did not have diabetes or a history of obesity-related cancer. Participants were divided into two groups, with half receiving GLP-1 injections like Mounjaro, Wegovy, and Ozempic, while the other half received standard diet and exercise consultations. Over an average follow-up of two years, those using GLP-1 medications were significantly less likely to develop cancer associated with obesity. Notably, men showed a nearly 70% reduction in risk, and there was a 58% decrease in endometrial cancer cases. However, the study noted that this risk reduction was not observed among black patients, suggesting the need for more research into underlying factors. The findings highlight the potential broader health impacts of GLP-1 drugs, prompting experts to recommend further studies to explore their role in cancer prevention.